Nanoform Finland Plc, the medicine performance-enhancing company, announced today that it has signed an agreement with a CDMO partner for implementation of Nanoform’s biologics technology at one of the Partner’s European facilities for aseptic manufacturing and fill and finish of biological products.
Headquartered in Europe, the CDMO partner is a global leader in aseptic manufacturing of biologics and can support projects ranging from early clinical to commercial manufacturing. The agreement represents an important step in advancing Nanoform’s biologics technology towards clinical application. The parties will establish a dedicated production line for Nanoform’s biologics technology within the CDMO’s existing aseptic manufacturing facility in Germany. The facility has existing capabilities for the manufacture of injectable biologics under Good Manufacturing Practice (GMP) standards, including aseptic processing and fill-and-finish.
For Nanoform’s customers, the collaboration provides an accelerated pathway from formulation and preclinical development at Nanoform through to GMP manufacture and supply of material for clinical trials and later commercial manufacturing. Combining Nanoform’s biologics technology and development capabilities with an established CDMO’s aseptic infrastructure, quality systems and manufacturing expertise accelerates the transition into clinical development.
Nanoform and the CDMO partner target GMP readiness during the second half of 2027 in order to support a planned first customer clinical trial of a subcutaneous ultra-high concentration suspension biologic product enabled by nanoforming. The agreement does not have an immediate material financial effect on Nanoform.
Edward Hæggström, Chief Executive Officer of Nanoform, commented:
“We are pleased to have identified an excellent partner to enable us to accelerate our customers’ entry to clinic with subcutaneous ultra-high concentration suspension products enabled by nanoforming. We look forward to the implementation work at the partner’s site during the coming months. Both we and our customers are impressed by the expertise and speed by which this cooperation has started.”
Christian Jones, Chief Commercial Officer of Nanoform, commented:
“Enabling clinical supply is fundamental for our customers and partners also on the biologics side. The partnership announced today will provide an accelerated pathway to clinical supply of GMP material with a CDMO partner that is a global leader in aseptic manufacturing and has a strong network to support our joint customers. Nanoform believes subcutaneous delivery will become the dominant standard for new and marketed biologics. Nanoform’s suspension formulations enable high drug concentrations with particle properties that are critical for suspension performance.”

